

1 December 2021

Stayble Therapeutics presented at Swedish Shareholders' Association's event Stora Aktiedagen Stockholm 2021

Stayble Therapeutics' CEO Andreas Gerward gave a presentation on 30 November 2021 at Stora Aktiedagen Stockholm 2021, an event arranged by Swedish Shareholders' Association's. The event, which takes place between 29 November and 2 December 2021, is a physical event with a studio audience that is broadcasted live via Swedish Shareholders' Association's YouTube channel.

CEO Andreas Gerward presented the Company, the development of the injection treatment STA363 for chronic disc-related low back pain, and positive interim results from the ongoing clinical phase 2b study.

The presentation from November 30 is available at:

<https://youtu.be/5isB5oucdJY>

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

E-mail: andreas.gerward@stayble.se

Phone: +46 730 808 397

Om Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient's life and to require minimal rehabilitation. The Company's focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble's vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain

Mangold Fondkommission AB is the Company's Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se. More information on www.staybletherapeutics.com.